CONFIRM anti-Thyroid Transcription Factor-1 (8G7G3/1) Mouse Monoclonal Primary Antibody

REF 790-4398

05479312001

IVD Σ 50



Figure 1. CONFIRM anti-TTF-1 (8G7G3/1) antibody staining of neoplastic cells in lung adenocarcinoma tissue.

INTENDED USE

CONFIRM anti-Thyroid Transcription Factor-1 (8G7G3/1) Mouse Monoclonal Primary Antibody is intended for laboratory use in the qualitative immunohistochemical detection of thyroid transcription factor-1 (TTF-1) by light microscopy in sections of formalin-fixed paraffin-embedded (FFPE) tissue stained on a BenchMark IHC/ISH instrument.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and with proper controls.

This antibody is intended for in vitro diagnostic (IVD) use.

SUMMARY AND EXPLANATION

CONFIRM anti-Thyroid Transcription Factor-1 (8G7G3/1) Mouse Monoclonal Primary Antibody (CONFIRM anti-TTF-1 (8G7G3/1) antibody) is a species and clone antibody produced against TTF-1. TTF-1 is a ~38 kDa homeodomain-containing nuclear transcription factor and is expressed in the thyroid and lung.[1,2] In normal thyroid tissue, TTF-1 is expressed in follicular and parafollicular cells.[1] In normal adult lung, TTF-1 is expressed only in type II pneumocytes and Clara cells.[1] In fetal lung, TTF-1 is detected in columnar nonciliated cells as early as 11 weeks of gestation.[1]

Tissue-specific exclusive expression of the thyroid gland and lung allows TTF-1 to be a useful marker for the classification of tumors arising in these organs.[3] Detection of TTF-1 protein by immunohistochemistry (IHC) with the CONFIRM anti-TTF-1 (8G7G3/1) antibody may be used to aid in the classification of neoplasms of the thyroid and lung. It may be used as part of a panel in IHC studies.

PRINCIPLE OF THE PROCEDURE

CONFIRM anti-TTF-1 (8G7G3/1) antibody binds to thyroid transcription factor protein in formalin-fixed paraffin-embedded (FFPE) tissue sections and exhibits a nuclear staining pattern. This antibody can be visualized using *ultra*View Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001) or OptiView DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001). Refer to the respective method sheets for further information.

MATERIAL PROVIDED

CONFIRM anti-TTF-1 (8G7G3/1) antibody contains sufficient reagent for 50 tests.

One 5 mL dispenser of CONFIRM anti-TTF-1 (8G7G3/1) antibody contains approximately 20 µg of a purified mouse monoclonal antibody.

The antibody is diluted in Tris-HCl with carrier protein, and 0.10% ProClin 300, a preservative.

Specific antibody concentration is approximately 4 µg/mL. There is no known non-specific antibody reactivity observed in this product.

CONFIRM anti-TTF-1 (8G7G3/1) antibody is a recombinant mouse monoclonal antibody produced as purified cell culture supernatant.

Refer to the appropriate VENTANA detection kit method sheet for detailed descriptions of: Principle of the Procedure, Material and Methods, Specimen Collection and Preparation for Analysis, Quality Control Procedures, Troubleshooting, Interpretation of Results, and Limitations.

MATERIALS REQUIRED BUT NOT PROVIDED

Staining reagents, such as VENTANA detection kits and ancillary components, including negative and positive tissue control slides, are not provided.

Not all products listed in the method sheet may be available in all geographies. Consult your local support representative.

The following reagents and materials may be required for staining but are not provided:

1. Recommended control tissue
2. Microscope slides, positively charged
3. Negative Control (Monoclonal) (Cat. No. 760-2014 / 05266670001)
4. OptiView DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001)
5. *ultra*View Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001)
6. EZ Prep Concentrate (10X) (Cat. No. 950-102 / 05279771001)
7. Reaction Buffer Concentrate (10X) (Cat. No. 950-300 / 05353955001)
8. LCS (Predilute) (Cat. No. 650-010 / 05264839001)
9. ULTRA LCS (Predilute) (Cat. No. 650-210 / 05424534001)
10. Cell Conditioning Solution (CC1) (Cat. No. 950-124 / 05279801001)
11. ULTRA Cell Conditioning Solution (ULTRA CC1) (Cat. No. 950-224 / 05424569001)
12. Hematoxylin II (Cat. No. 790-2208 / 05277965001)
13. Bluing Reagent (Cat. No. 760-2037 / 05266769001)
14. General purpose laboratory equipment
15. BenchMark IHC/ISH instrument

STORAGE AND STABILITY

Upon receipt and when not in use, store at 2-8°C. Do not freeze.

To ensure proper reagent delivery and the stability of the antibody, replace the dispenser cap after every use and immediately place the dispenser in the refrigerator in an upright position.

Every antibody dispenser is expiration dated. When properly stored, the reagent is stable to the date indicated on the label. Do not use reagent beyond the expiration date.

SPECIMEN PREPARATION

Routinely processed FFPE tissues are suitable for use with this primary antibody when used with VENTANA detection kits and BenchMark IHC/ISH instruments. The recommended tissue fixative is 10% neutral buffered formalin.[4] Sections should be cut at approximately 4 µm in thickness and mounted on positively charged slides. Slides should be stained immediately, as antigenicity of cut tissue sections may diminish over time. Ask your Roche representative for a copy of "Recommended Slide Storage and Handling" for more information.

It is recommended that positive and negative controls be run simultaneously with unknown specimens.

WARNINGS AND PRECAUTIONS

1. For in vitro diagnostic (IVD) use.
2. For professional use only.
3. Do not use beyond the specified number of tests.
4. ProClin 300 solution is used as a preservative in this reagent. It is classified as an irritant and may cause sensitization through skin contact. Take reasonable precautions when handling. Avoid contact of reagents with eyes, skin, and mucous membranes. Use protective clothing and gloves.
5. Positively charged slides may be susceptible to environmental stresses resulting in inappropriate staining. Ask your Roche representative for more information on how to use these types of slides.
6. Materials of human or animal origin should be handled as biohazardous materials and disposed of with proper precautions. In the event of exposure, the health directives of the responsible authorities should be followed.[5,6]
7. Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
8. Avoid microbial contamination of reagents as it may cause incorrect results.
9. For further information on the use of this device, refer to the BenchMark IHC/ISH instrument User Guide, and instructions for use of all necessary components located at navifyportal.roche.com.
10. Consult local and/or state authorities with regard to recommended method of disposal.

11. Product safety labeling primarily follows EU GHS guidance. Safety data sheet available for professional user on request.
12. To report suspected serious incidents related to this device, contact the local Roche representative and the competent authority of the Member State or Country in which the user is established.

This product contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Table 1. Hazard information.

Hazard	Code	Statement
WARNING 	H317	May cause an allergic skin reaction.
	H412	Harmful to aquatic life with long lasting effects.
	P261	Avoid breathing mist or vapours.
	P273	Avoid release to the environment.
	P280	Wear protective gloves.
	P333 + P313	If skin irritation or rash occurs, get medical advice/ attention.
	P362 + P364	Take off contaminated clothing and wash it before reuse.
	P501	Dispose of contents/ container to an approved waste disposal plant.

This product contains CAS # 55965-84-9, a reaction mass of: 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)

STAINING PROCEDURE

VENTANA primary antibodies have been developed for use on BenchMark IHC/ISH instruments in combination with VENTANA detection kits and accessories. Refer to the tables below for recommended staining protocols.

This antibody has been optimized for specific incubation times but the user must validate results obtained with this reagent.

The parameters for the automated procedures can be displayed, printed and edited according to the procedure in the instrument User Guide. Refer to the appropriate VENTANA detection kit method sheet for more details regarding immunohistochemistry staining procedures.

For more details on the proper use of this device, refer to the inline dispenser method sheet associated with P/N 790-4398.

Table 2. Recommended staining protocol for CONFIRM anti-TTF-1 (8G7G3/1) antibody with *ultra*View Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type	Method	
	GX	ULTRA or ULTRA PLUS[a]
Deparaffinization	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1, Standard	ULTRA CC1, 64 minutes, 95°C
Antibody (Primary)	32 minutes, 37°C	32 minutes, 36°C
Counterstain	Hematoxylin II, 4 minutes	
Post Counterstain	Bluing, 4 minutes	

[a] Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Table 3. Recommended staining protocol for CONFIRM anti-TTF-1 (8G7G3/1) antibody with OptiView DAB IHC Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type	Method	
	GX	ULTRA or ULTRA PLUS[a]
Deparaffinization	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1 64 minutes	ULTRA CC1 64 minutes, 100°C
Pre-Primary Peroxidase Inhibitor	Selected	Selected
Antibody (Primary)	32 minutes, 37°C	32 minutes, 36°C
OptiView HQ Linker	8 minutes (default)	
OptiView HRP Multimer	8 minutes (default)	
Counterstain	Hematoxylin II, 4 minutes	
Post Counterstain	Bluing, 4 minutes	

[a] Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Due to variation in tissue fixation and processing, as well as general lab instrument and environmental conditions, it may be necessary to increase or decrease the primary antibody incubation, cell conditioning or protease pretreatment based on individual specimens, detection used, and reader preference. For further information on fixation variables, refer to "Immunohistochemistry Principles and Advances."[7]

NEGATIVE REAGENT CONTROL

In addition to staining with CONFIRM anti-TTF-1 (8G7G3/1) antibody, a second slide should be stained with the appropriate negative control reagent.

POSITIVE TISSUE CONTROL

Optimal laboratory practice is to include a positive control section on the same slide as the test tissue. This helps identify any failures applying reagents to the slide. Tissue with weak positive staining is best suited for quality control. Control tissue may contain both positive and negative staining elements and serve as both the positive and negative control. Control tissue should be fresh autopsy, biopsy, or surgical specimen, prepared or fixed as soon as possible in a manner identical to test sections.

Known positive tissue controls should be utilized only for monitoring performance of reagents and instruments, not as an aid in determining specific diagnosis of test samples. If the positive tissue controls fail to demonstrate positive staining, results of the test specimen should be considered invalid.

Examples of positive control tissues for this antibody are lung adenocarcinoma tissue, normal lung, or normal thyroid tissue.

STAINING INTERPRETATION / EXPECTED RESULTS

The cellular staining pattern for CONFIRM anti-TTF-1 (8G7G3/1) antibody is nuclear.

SPECIFIC LIMITATIONS

CONFIRM anti-TTF-1 (8G7G3/1) antibody demonstrated cytoplasmic staining of hepatocytes in normal liver tissue. This staining pattern in the liver has been previously reported with clone 8G7G3/1 and is the result of an affinity to an unknown component in the cytoplasm of hepatocytes.[8]

OptiView DAB detection system is generally more sensitive than *ultra*View DAB. The user must validate the results obtained with this reagent and detection systems.

All assays might not be registered on every instrument. Please contact your local Roche representative for more information.

PERFORMANCE CHARACTERISTICS

ANALYTICAL PERFORMANCE

Staining tests for sensitivity, specificity, and precision were conducted and the results are listed below.

Sensitivity and Specificity

Table 4. Sensitivity/Specificity of CONFIRM anti-TTF-1 (8G7G3/1) antibody was determined by testing FFPE normal tissues.

Tissue	# positive / total cases	Tissue	# positive / total cases
Cerebrum	0/3	Small intestine	0/4
Cerebellum	0/4	Colon	0/3
Brain	0/1	Rectum	0/3
Adrenal gland[a]	0/4	Liver[c]	0/4
Ovary	0/3	Salivary gland	0/4
Pancreas	0/4	Kidney	0/5
Parathyroid gland	0/3	Prostate[a]	0/4
Pituitary gland	0/3	Bladder	0/4
Testis	0/3	Ureter	0/2
Thyroid	9/9	Endometrium	0/4
Breast	0/4	Fallopian tube	0/3
Spleen [a]	0/3	Placenta	0/3
Tonsil [a]	0/3	Cervix	0/4
Thymus	0/3	Skeletal muscle	0/3
Bone marrow	0/3	Skin	0/4
Lung[b]	8/8	Nerve	0/3
Heart	0/3	Spinal cord	0/2
Esophagus	0/3	Mesothelium	0/3
Stomach	0/4	Eye	0/2

[a] Tissue evaluated includes normal and hyperplasia.

[b] Tissue evaluated includes normal and inflammatory.

[c] Weak to moderate granular cytoplasmic staining. Please see the Specific Limitations section for more information

Table 5. Sensitivity/Specificity of CONFIRM anti-TTF-1 (8G7G3/1) antibody was determined by testing a variety of FFPE neoplastic tissues.

Pathology	# positive / total cases
Astrocytoma (Brain)	0/1
Meningioma, fibroblastic (Brain)	0/2
Anaplastic meningioma (Brain)	0/1
Adenocarcinoma (Head and neck)	0/1
Squamous cell carcinoma (Head and neck)	0/1
Adenoma (Adrenal gland)	0/1
Adrenocortical carcinoma (Adrenal gland)	0/1
Granulosa cell tumor (Ovary)	0/1
Adenocarcinoma (Ovary)	0/2
Adenocarcinoma (Pancreas)	0/1
Seminoma (Testis)	0/2
Adenoma (Thyroid)	2/3
Follicular carcinoma (Thyroid)	15/18
Papillary carcinoma (Thyroid)	62/65
Medullary Carcinoma (Thyroid)	6/10
Fibroadenoma (Breast)	0/2
Invasive ductal carcinoma (Breast)	0/3
Metastatic breast ductal carcinoma (Lymph node)	0/1
Clear cell carcinoma (Lung)	0/1
Large cell carcinoma (Lung)	1/1
Small cell carcinoma (Lung)	6/18
Squamous cell carcinoma (Lung)	2/49
Adenosquamous carcinoma (Lung)	0/9
Adenocarcinoma (Lung)	37/52
Adenocarcinoma in situ (Lung)	3/11
Papillary carcinoma (Lung)	0/1
Neuroendocrine carcinoma, typical carcinoid tumor (Lung)	3/13
Metastatic cancer (Lung)	0/1
Squamous cell carcinoma (Esophagus)	0/3
Metastatic esophagus squamous cell carcinoma (Lymph node)	0/1
Adenocarcinoma (Stomach)	0/3
Adenoma (Small intestine)	0/1
Adenocarcinoma (Small intestine)	0/1
Adenoma (Colon)	0/1
Adenocarcinoma (Colon)	0/3
Metastatic colon signet ring cell carcinoma (Ovary)	0/1
Metastatic colon adenocarcinoma (Liver)	0/1
Adenocarcinoma (Rectum)	0/3
Hepatocellular carcinoma (Liver)	0/4
Pleomorphic adenoma (Head and neck, salivary gland)	0/1
Adenoid cystic carcinoma (Head and neck, salivary gland)	0/1
Clear cell carcinoma (Kidney)	0/1
Adenocarcinoma (Prostate)	0/2
Squamous cell carcinoma (Cervix)	0/2
Adenocarcinoma (Endometrium)	0/2
Squamous cell carcinoma (Skin)	0/1
Melanoma	0/1
Hodgkin lymphoma	0/1
Anaplastic large cell lymphoma	0/1
B-cell Lymphoma; NOS	0/1
Urothelial carcinoma (Bladder)	0/2
Osteosarcoma (Bone)	0/1

Pathology	# positive / total cases
Chondrosarcoma (Bone)	0/1

Precision

Precision studies for CONFIRM anti-TTF-1 (8G7G3/1) antibody were completed to demonstrate:

- Between lot precision of the antibody.
- Within run and between day precision on a BenchMark ULTRA instrument.
- Between instrument precision on the BenchMark GX and BenchMark ULTRA / ULTRA PLUS instrument.
- Between platform precision between BenchMark GX and BenchMark ULTRA / ULTRA PLUS instruments.

All studies met their acceptance criteria.

Precision on the BenchMark ULTRA PLUS instrument was demonstrated using representative assays. Studies included Within-run Repeatability, Between-day and Between-run Intermediate Precision. All studies met their acceptance criteria.

CLINICAL PERFORMANCE

Clinical performance data relevant to the intended purpose of CONFIRM anti-TTF-1 (8G7G3/1) antibody were assessed by systematic review of the literature. The data gathered support the use of the device in accordance with its intended purpose.

REFERENCES

1. Ordonez NG. Value of Thyroid Transcription Factor-1 Immunostaining in Tumor Diagnosis: A Review and Update. Appl Immunohistochem Mol Morphol. 2012;20(5):429-444.
2. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 5th Edition. 5th ed. Philadelphia, PA: Elsevier; 2019.
3. Tan D, Li Q, Deed G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Human Pathol. 2003;34:597-604.
4. Carson FL, Cappellano C. Histotechnology; A Self-Instructional Text, 5th edition. American Society for Clinical Pathology Press; 2020, 2022.
5. Occupational Safety and Health Standards: Occupational exposure to hazardous chemicals in laboratories. (29 CFR Part 1910.1450). Fed. Register.
6. Directive 2000/54/EC of the European Parliament and Council of 24 June 2020 on the protection of workers from risks related to exposure to biological agents at work.
7. Roche PC, Hsi ED. Immunohistochemistry-Principles and Advances. Manual of Clinical Laboratory Immunology, 6th edition. In: NR Rose, ed. ASM Press; 2002.
8. Bejarano PA. Incidence and Significance of Cytoplasmic Thyroid Transcription Prostatic transitional cell carcinoma Factor-1 Immunoreactivity. Arch Pathol Lab Med. 2003;127:193-195.

NOTE: A point (period/stop) is always used in this document as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

The summary of safety and performance can be found here:

https://ec.europa.eu/tools/eudamed

Symbols

Ventana uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see elabdoc.roche.com/symbols for more information).

GTIN	Global Trade Item Number
Rx only	For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

REVISION HISTORY

Rev	Updates
H	Updates to Warnings and Precautions section.

INTELLECTUAL PROPERTY

For USA: Rx only

CONTACT INFORMATION

Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, AZ 85755
USA
+1 520 887 2155
+1 800 227 2155 (USA)

www.roche.com

EC REP

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany
+800 5505 6606

CE 0123